1. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. (January 2022) Authors: Vermeire, Severine; Lakatos, Peter L; Ritter, Timothy; Hanauer, Stephen; Bressler, Brian; Khanna, Reena; Isaacs, Kim; Shah, Saumin; Kadva, Alysha; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Eden, Christopher; Zhang, Wenhui; Feagan, Brian G; Abraham, Philip; Acir Crip... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. (January 2022) Authors: Rubin, David T; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter D R; Mishkin, Daniel S; Arrisi, Pablo; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panés, Julian; Abdulkhakov, Rustem; Abu ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗